Celltrion Pharm Inc.
KOSDAQ
₩39,400.00
-1.50%
Delayed · cached 15 min
Fair value analysis
068760
Celltrion Pharm Inc.
₩39,400.00
Close used for this calculation
₩14,498.08Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
38/100
Quality radar
Consensus fair value
₩14,498.08
Above FV▼ -63.2% against the close used
Model range ₩2,037.21 – ₩37,830.00
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩2,037.21Fair value₩14,498.08Bull₩37,830.00
FairClose
52-week traded range
52W low ₩38,000.0052W high ₩46,100.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Celltrion Pharm Inc. closed at ₩39,400.00, 171.8% above the consensus fair value of ₩14,498.08 drawn from 9 valuation models.
Financial DNA score 38/100 — Average. P/E of 67.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩11,611.68
-70.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₩10,515.52
-73.3%
√(22.5 × EPS × BVPS)
EPS=585, BVPS=8400.85 · outside Graham range (P/E 67.4, P/B 4.7) — asset-light, treat as a rough floor
Graham Formula
₩37,830.00
-4.0%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=20%, FD=3.3%
P/E Fair Value
₩11,700.00
-70.3%
EPS × 20x (sector P/E)
EPS=585, Sector P/E=20x
Peter Lynch (PEG)
₩17,550.00
-55.5%
EPS × Growth% (PEG = 1 is fair)
EPS=585, g=30%
EV/EBITDA
₩6,518.30
-83.5%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=23.63B
Book Value (P/B)
₩2,037.21
-94.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=8400.85, ROE=7%, g=6%, r=10%
Reverse DCF
₩39,400.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 23.6% | Historical: 143.4%
Margin of Safety
₩13,435.72
-65.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=17914.3, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.